What is the manufacturer's production capacity?

The company produces over 1200 million bottles yearly, including 40 million soft plastic bottles in various dosages.

Where are the products exported to?

Products are sold to regions in South America, Africa, Asia, Oceania, and the Middle East.

What payment terms are accepted?

Accepted payment terms include LC and T/T.

Ringer Lactate Injection /Ringer Infusion

Name: Ringer Lactate Injection /Ringer Infusion
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2047967482

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.17-0.20

10,000 Pieces

Sample price:US$0.20/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Infusion

Model NO.

1000ml

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Infusion

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

15bottles/Carton

Specification

1000ml

Trademark

SHIMEN

Origin

China

HS Code

3004909099

Production Capacity

1000000/Year

Key features

Electrolyte Balance Correction: Adjusts equilibrium of humor electrolyte acid and alkali, treats metabolic acid toxicosis.

Hyperpotassaemia Treatment: Sodium lactate corrects acid toxicosis and helps potassium enter cells from blood.

Clear Liquid Formulation: Product is a colorless clear liquid suitable for intravenous infusion.

Comprehensive Ingredient Profile: Contains Sodium Lactate, Sodium Chloride, Potassium Chloride, and Calcium Chloride per 1000ml.

Suitable for All Ages: Indicated for use in elderly, children, and adults.

GMP Certified Manufacturing: Manufacturer holds GMP approval by SFDA of China with advanced production capabilities.

High Volume Production Capacity: Yearly output exceeds 1200 million bottles including 40 million soft plastic bottles.

Global Market Presence: Products sold to South America, Africa, Asia, Oceania, and Middle East regions.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤18hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.